Borgeson Blake 4

What Happened

• Blake Borgeson, a director of Recursion Pharmaceuticals (RXRX), sold 40,000 shares in an open-market transaction on July 7, 2026. The weighted average sale price was $3.96 per share for total proceeds of approximately $158,500. This was a sale (code S), not a purchase.

Key Details

• Transaction date: July 7, 2026.
• Prices: executed in multiple trades at $3.95–$4.00; reported weighted average price $3.96 (total ≈ $158,500). The filer will provide per-trade breakdown on request (see footnote).
• Shares owned after transaction: not disclosed in the information provided in this summary.
• Footnotes: (F1) Sale was made pursuant to a Rule 10b5-1 trading plan adopted August 31, 2025. (F2) Multiple trades at $3.95–$4.00; weighted-average price reported.
• Timeliness: Form 4 was filed July 9, 2026 (within the typical two-business-day filing window).

Context

• The sale was executed under a pre-established 10b5-1 plan, which often indicates the transactions were prearranged and not necessarily a reflection of current sentiment. Sales are generally less informative than purchases about insider confidence in the company’s prospects.